SEARCH

SEARCH BY CITATION

References

  • 1
    WHO/ICO Information Centre on HPV and Cervical Cancer Human Papillomavirus and Related Cancers in Thailand. Summary Report 2010. [www. who. int/hpvcentre]. Last accessed 20 June 2010.
  • 2
    Trope LA, Chumworathayi B, Blumenthal PD. Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-et Province, Thailand. Int J Gynecol Cancer 2009;19:14328.
  • 3
    Domingo EJ, Noviani R, Noor MR, Ngelangel CA, Limpaphayom KK, Thuan TV, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine 2008;26 (Suppl 12):M719.
  • 4
    Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:32933.
  • 5
    Ronco G, Giorgi Rossi P. New paradigms in cervical cancer prevention: opportunities and risks. BMC Womens Health 2008;8:23.
  • 6
    Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues 2010;20:3542.
  • 7
    Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398406.
  • 8
    Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 2003;361:81420.
  • 9
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:138594.
  • 10
    Sanghvi H, Limpaphayom KK, Plotkin M, Charurat E, Kleine A, Lu E, et al. Cervical cancer screening using visual inspection with acetic acid: operational experiences from Ghana and Thailand. Reprod Health Matters 2008;16:6777.
  • 11
    Tangcharoensathien V, Limwattananon S, Chaugwon R. Research for development of an optimal strategy for prevention and control of cervical cancer in Thailand. Research report submitted the World Bank. Nonthaburi: Ministry of Public Health, Thailand. 2008. [www.hitap.net/index_en.php]. Last accessed 30 June 2010.
  • 12
    Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V, Koonsaeng S. Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers. Southeast Asian J Trop Med Public Health 2009;40:104856.
  • 13
    Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998;19:12552.
  • 14
    Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O’Shea MK, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007;25:625770.
  • 15
    Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007;166:13750.
  • 16
    Kim JJ, Kobus KE, Diaz M, O’Shea M, Van Minh H, Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008;26:401524.
  • 17
    WHO. WHO Life Tables, 2008. 2008 [www.who.int/healthinfo/statistics/mortality_life_tables/en/]. Last accessed 5 November 2010.
  • 18
    Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:124656.
  • 19
    Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007;5:11.
  • 20
    Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:215868.
  • 21
    Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008;99:2308.
  • 22
    World Bank World Development Indicators, WDI Online. [www.worldbank.org]. Last accessed 20 June 2010.
  • 23
    World Health Organization Statistical Information System: CHOICE (Choosing Interventions that are Cost Effective) [www.who.int/choice/en/]. Last accessed 17 June 2010.
  • 24
    International Labour Organization (ILO). [www.ilo.org/global/lang-en/index.htm]. Last accessed 10 June 2010.
  • 25
    Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:310715.
  • 26
    Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 27
    Drummond MF. Methods for the Economic Evaluation of Health Care Programmes. 2nd edn. Oxford, New York: Oxford University Press, 1997.
  • 28
    Edejer TT-T. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization, 2003.
  • 29
    WHO Guidelines for estimating costs of introducing new vaccines into the national immunization system 2002. [http://whqlibdoc.who.int/hq/2002/WHO_V&B_02.11.pdf]. Last accessed 29 July 2010.
  • 30
    World Bank: International Bank for Reconstruction and Development/World Bank Group. World Development Indicators. World population projections. [http://devdata.worldbank.org/data-query/]. Last accessed 30 June 2010.
  • 31
    Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006;24 (Suppl 3):S17886.
  • 32
    Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009;199:92635.
  • 33
    Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:30114.